Search

Rotenone

Rotenone is an isoflavone compound that naturally occurs in the jicama vine plant as well as many Fabaceae plants. It has broad spectrum insecticide and pesticide activity and is also toxic to fish.

Omega-6 fatty acids

Arachidonic acid, which is a main precursor of eicosanoids, is an example of omega-6 (n-6) polyunsaturated fatty acids. Vegetable oil is a major dietary sources of omega-6 fatty acids. … Omega-6 fatty acids are polyunsaturated fatty acids with a final carbon-carbon double bond in the n-6 position, that is, the sixth bond, counting from the methyl end.

Hydrogenated soybean oil

It may be found in cosmetics and personal care products as an emollient or skin conditioning agent. … Linolenic acid and stearic acids are contained in hydrogenated soybean oil, but hydrogenation results in reduced unsaturation in linolenic acid.

Oxprenolol

A beta-adrenergic antagonist used in the treatment of hypertension, angina pectoris, arrhythmias, and anxiety.

Thiethylperazine

A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins.

Flavin adenine dinucleotide

(Lehninger, Principles of Biochemistry, 1982, p972) Flavin adenine dinucleotide is approved for use in Japan under the trade name Adeflavin as an ophthalmic treatment for vitamin B2 deficiency.

Methoxyamine

Diethyltryptamine

Diethyltryptamine (DET) is an orally active hallucinogenic agent and a substituted form of tryptamine.

Quinupristin

The combination of the two components acts synergistically and is more effective in vitro than each component alone. … Quinupristin/dalfopristin is a combination of two antibiotics used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium.

Amrubicin

In 2002, Amrubicin was approved and launched for sale in Japan based on Phase 2 efficacy data in both SCLC and NSCLC. … Amrubicin is a third-generation synthetic anthracycline currently in development for the treatment of small cell lung cancer. Pharmion licensed the rights to Amrubicin in November 2006.